b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">28925793</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>01</Month>\n            <Day>11</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>01</Month>\n            <Day>11</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">2164-554X</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>14</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>01</Month>\n                        <Day>02</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Human vaccines &amp; immunotherapeutics</Title>\n                <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-\xce\xb2Gal and MVA-MUC1 (TG4010) in a murine tumor model.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>140-145</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2017.1373921</ELocationID>\n            <Abstract>\n                <AbstractText>TG4010, a Modified Vaccinia virus Ankara (MVA) expressing human mucin1 (MUC1) has demonstrated clinical benefit for patients suffering from advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy. To support its development, preclinical experiments were performed with either TG4010 or \xce\xb2-galactosidase-encoding MVA vector (MVA-\xce\xb2gal) in mice presenting tumors in the lung. Tumor growth was obtained after intravenous injection of CT26 murine colon cancer cells, engineered to express either MUC1 or \xce\xb2gal. Mice showed increased survival rates after repeated intravenous injections of TG4010 or MVA-\xce\xb2gal, compared to an empty MVA control vector. Treatment with MVA vectors led to the accumulation of CD3<sup>dim</sup>CD8<sup>dim</sup> T cells, with two subpopulations characterized as KLRG1<sup>+</sup>CD127<sup>-</sup> short-lived effector cells (SLECs), and KLRG1<sup>-</sup>CD127<sup>-</sup> early effector cells (EECs) comprising cells releasing IFN\xce\xb3, Granzyme B and CD107a upon antigen-specific peptide stimulation. EECs were characterized by an up-regulation of PD-1. Tumor growth in the diseased lung correlated with the appearance of PD1<sup>+</sup> Treg cells that partially disappeared after TG4010 treatment. At late stage of tumor development in the lung, PD-L1 was detected on CD45<sup>-</sup> tumor cells, on CD4<sup>+</sup> cells, including Treg cells, on CD3<sup>+</sup>CD8<sup>+</sup> and CD3<sup>dim</sup>CD8<sup>dim</sup> T lymphocytes, on NK cells, on MDSCs and on alveolar macrophages. We demonstrated that targeting the PD-1/PD-L1 pathway with blocking monoclonal antibodies several days after TG4010 treatment, at late stage of tumor development, enhanced the therapeutic protection induced by the vaccine, supporting the ongoing clinical evaluation of TG4010 immunotherapy in combination with Nivolumab.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Remy-Ziller</LastName>\n                    <ForeName>Christelle</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Department of Oncoimmunology , Transgene S.A. , Parc d\'Innovation, Illkirch-Graffenstaden , Cedex , France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Thioudellet</LastName>\n                    <ForeName>Christine</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Department of Oncoimmunology , Transgene S.A. , Parc d\'Innovation, Illkirch-Graffenstaden , Cedex , France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hortelano</LastName>\n                    <ForeName>Julie</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Department of Oncoimmunology , Transgene S.A. , Parc d\'Innovation, Illkirch-Graffenstaden , Cedex , France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gantzer</LastName>\n                    <ForeName>Murielle</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Department of Oncoimmunology , Transgene S.A. , Parc d\'Innovation, Illkirch-Graffenstaden , Cedex , France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nourtier</LastName>\n                    <ForeName>Virginie</ForeName>\n                    <Initials>V</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Department of Oncoimmunology , Transgene S.A. , Parc d\'Innovation, Illkirch-Graffenstaden , Cedex , France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Claudepierre</LastName>\n                    <ForeName>Marie-Christine</ForeName>\n                    <Initials>MC</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Department of Oncoimmunology , Transgene S.A. , Parc d\'Innovation, Illkirch-Graffenstaden , Cedex , France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sansas</LastName>\n                    <ForeName>Benoit</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Department of Oncoimmunology , Transgene S.A. , Parc d\'Innovation, Illkirch-Graffenstaden , Cedex , France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pr\xc3\xa9ville</LastName>\n                    <ForeName>Xavier</ForeName>\n                    <Initials>X</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Department of Oncoimmunology , Transgene S.A. , Parc d\'Innovation, Illkirch-Graffenstaden , Cedex , France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bendjama</LastName>\n                    <ForeName>Ka\xc3\xafdre</ForeName>\n                    <Initials>K</Initials>\n                    <Identifier Source="ORCID">0000-0003-2185-9116</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>a Department of Oncoimmunology , Transgene S.A. , Parc d\'Innovation, Illkirch-Graffenstaden , Cedex , France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Quemeneur</LastName>\n                    <ForeName>Eric</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Department of Oncoimmunology , Transgene S.A. , Parc d\'Innovation, Illkirch-Graffenstaden , Cedex , France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rittner</LastName>\n                    <ForeName>Karola</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Department of Oncoimmunology , Transgene S.A. , Parc d\'Innovation, Illkirch-Graffenstaden , Cedex , France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2017</Year>\n                <Month>10</Month>\n                <Day>18</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Hum Vaccin Immunother</MedlineTA>\n            <NlmUniqueID>101572652</NlmUniqueID>\n            <ISSNLinking>2164-5515</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C060192">MUC1 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D018396">Mucin-1</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C518275">TG4010</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>31YO63LBSN</RegistryNumber>\n                <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>\n                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019496" MajorTopicYN="N">Cancer Vaccines</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>\n                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018396" MajorTopicYN="N">Mucin-1</DescriptorName>\n                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014616" MajorTopicYN="N">Vaccinia virus</DescriptorName>\n                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Modified Vaccinia virus Ankara</Keyword>\n            <Keyword MajorTopicYN="Y">PD-1</Keyword>\n            <Keyword MajorTopicYN="Y">PD-L1</Keyword>\n            <Keyword MajorTopicYN="Y">TG4010</Keyword>\n            <Keyword MajorTopicYN="Y">immune checkpoint blockade</Keyword>\n            <Keyword MajorTopicYN="Y">lung cancer</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>9</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>1</Month>\n                <Day>12</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>9</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">28925793</ArticleId>\n            <ArticleId IdType="doi">10.1080/21645515.2017.1373921</ArticleId>\n            <ArticleId IdType="pmc">PMC5791558</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>J Immunol. 2005 Feb 15;174(4):1922-31</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15699119</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 1980 Jul;40(7):2142-6</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">6992981</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nature. 2014 Nov 27;515(7528):568-71</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25428505</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Immunol. 1995 May 1;154(9):4685-92</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">7722321</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Science. 2015 Apr 3;348(6230):124-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25765070</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Vaccine. 2017 Jan 23;35(4):577-585</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28012777</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Immunol Res. 2014 Dec;2(12):1163-74</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25168392</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Virol. 2014 May;88(10):5242-55</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24574403</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Treat Options Oncol. 2014 Dec;15(4):658-69</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25096781</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2016 Feb;17 (2):212-223</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26727163</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nature. 2017 Jan 18;541(7637):321-330</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28102259</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 2004 Feb 1;64(3):1140-5</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">14871849</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Exp Med. 2000 Oct 2;192(7):1027-34</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11015443</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Pathol Oncol Res. 2016 Apr;22(2):331-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26552662</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Cancer. 2010 Dec 15;127(12):2893-917</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21351269</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Immunol Immunother. 2013 Oct;62(10):1547-51</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23979447</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Immunity. 2013 Jul 25;39(1):1-10</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23890059</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2011 Nov;12(12):1125-33</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22019520</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Sci Transl Med. 2012 Mar 28;4(127):127ra37</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22461641</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Am J Respir Cell Mol Biol. 2013 Oct;49(4):503-10</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23672262</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Med. 2002 Aug;8(8):793-800</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12091876</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Onco Targets Ther. 2015 Jul 23;8:1831-3</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26229490</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Immunol. 2015 Jun 15;194(12):5801-11</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25934860</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Sci Rep. 2015 Jul 20;5:12264</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26191658</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'